GLP-1 Food Industry Short

Scott Galloway proposes capitalizing on the GLP-1 drug revolution (medications like Ozempic and Wegovy) by shorting food industry stocks, particularly targeting companies that will be impacted by changing consumption patterns as these drugs become more widespread.

Key Points:

• Market Opportunity:

  • $1.7 trillion annual obesity-related costs in US economy
  • GLP-1 drugs reduce food cravings and consumption
  • Currently costs $500-1000 per month
  • Growing adoption rate, starting with wealthy consumers

• Investment Strategy:

  • Short food industry stocks
  • Specific targets mentioned:
    • McDonald's
    • Arby's
    • Other food service companies

• Market Impact Factors:

  • Users eat significantly less food
  • Drug requires increasing dosage over time
  • Affects multiple behavioral patterns:
    • 60% reduction in alcohol consumption
    • Reduced food cravings
    • Changes in general consumption habits

• Secondary Effects:

  • Potential impact on healthcare companies
  • Hospital networks could face reduced demand
  • Possible reduction in obesity-related medical procedures
  • Could affect vaccine manufacturers due to healthier population

Scott believes this represents a major market disruption opportunity, stating "I look at this category and how much money is in this category and it's gonna happen it's just there's never been a business there's never been a carcass so tempting so bloated swimming so slowly."